Logo

Grünenthal Entered into an Agreement with Bayer to Acquire Nebido for Male Hypogonadism Associated with Testosterone Deficiency

Share this
Grünenthal Entered into an Agreement with Bayer to Acquire Nebido for Male Hypogonadism Associated with Testosterone Deficiency

Grünenthal Entered into an Agreement with Bayer to Acquire Nebido for Male Hypogonadism Associated with Testosterone Deficiency

Shots:

  • Grünenthal & Bayer collaborated to acquire Nebido for ~$500M and the transaction is expected to close at the end of 2022. Grünenthal will acquire the global rights to Nebido
  • The divestment is part of an ongoing transformation of the pharmaceuticals business which focuses on healthcare innovation. Nebido is used for the treatment of male hypogonadism & is available to patients in ~80 countries globally & is patented until 2024 in the EU and 2027 in the US
  • The product is expected to add $100.38M to Grünenthal's EBITDA in 2023. In the past few years, Grünenthal has invested ~$2.008B in profitable M&A transactions, leading to a markedly increased profitability

Ref: PRNewswire | Image: Bayer 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions